CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression

Area of Science:

• Molecular Biology
• Neuroscience
• Gene Therapy

Background:

• Cell-type-specific promoters are crucial for targeted gene therapy but often exhibit low transcriptional activity.
• The human cytomegalovirus (CMV) immediate-early gene enhancer is known to boost promoter activity.
• The platelet-derived growth factor B-chain (PDGF-beta) promoter is a neuron-specific promoter.

Purpose of the Study:

• To investigate if the CMV enhancer can improve neuronal transgene expression driven by the PDGF-beta promoter.
• To create and test a hybrid promoter combining the CMV enhancer and PDGF-beta promoter for enhanced neuronal gene delivery.

Main Methods:

• Constructed a hybrid promoter by inserting a CMV enhancer fragment upstream of the PDGF-beta promoter.
• Complexed the hybrid promoter plasmid with polyethylenimine for in vitro and in vivo gene transfer.
• Assessed reporter gene expression (luciferase) in cultured neural cells and in rat brain (hippocampus, striatum).

Main Results:

• The hybrid promoter significantly increased reporter gene expression in cultured cells compared to PDGF-beta or CMV enhancer alone.
• In cultured neural cells, the hybrid promoter achieved expression levels comparable to or exceeding the robust CMV immediate-early promoter.
• In rat brains, the hybrid promoter demonstrated neuronal specificity, driving expression primarily in neurons with 10-fold higher levels than PDGF-beta alone, lasting over 4 weeks.

Conclusions:

• The novel hybrid promoter effectively enhances neuronal transgene expression.
• This construct offers improved transcriptional activity and duration for gene expression in neurons.
• The developed gene regulatory element holds promise for advancing gene therapy in neurological disorders and neuroscience research.